SBIR/STTR Research Award
TOPIC 324 PHASE I 9 MONTH FUNDING; NOVEL IMAGING AGENTS T EXPAND TE CLINICAL TOOL
Award amount
$249,975Program and phase
SBIR · Phase IAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ROCKLAND IMMUNOCHEMICALS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- NFKNUGEMMY18
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
Medical imaging and targeted therapy are the central components in the clinical management of cancer patients. Rockland Immunochemicals, Inc. is teaming up with Abzyme Therapeutics LLC to develop novel imaging agents that can be used in both cancer diagnosis and targeted therapy. In this phase I proposal, high-affinity camelid single domain antibodies to three cancer biomarkers HER2, EGFR and mesothelin will be developed. The antibodies will be directionally conjugated to near-infrared spectrum fluorescentdyes. Properties of the nanobody, including in vivo clearance, rapid tumor accumulation, in vivo stability and bioavailability, will be investigated in tumor xenograft animal models. In the Phase II, selected antibodies will be conjugated with chelators for radiolabeling with metal radionuclides. Pharmacokinetic, pharmacodynamics, immunogenic and toxicological characteristics of agents will be investigated in animal models to obtain data necessary for filing an Investigational New Drug application. PUBLIC HEALTH RELEVANCE
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- IGF OT IGF SYSTEMIC PRE TARGETED RADIOIMMUNOTHERAPY WITH BISPECIFIC NANOBODIES FOR CANCER TREATMENT
- Developing a Point-of-Care Device for the Diagnosis of Sickle Cell Disease in Low Resource Settings
- Synthetic antibodies for monitoring modified RNAs
- SBIR TOPIC 229, PHASE II: PHARMACODYNAMIC ASSAY FOR AKT FOR USE WITH PI3K/AKT/MTOR INHIBITORS
- TAS::75 0849::TAS SBIR TOPIC 292 PHASE I DEVELOPMENT OF MOLECULAR PHARMACODYNAMIC ASSAYS FOR TARGETED THERAPIES
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
11 SBIR/STTR records share this UEI (2008–2016). Reported award amounts total $3,800,913. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services